Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P Randall

Showing results (211-220 of 213) with videos related to

Pageof 22
Sort By:
You have reached the last page of results.This site can display upto 213 results.
Genetic Testing|January 1, 1997
The 22q11.2 deletion: screening, diagnostic workup, and outcome of results; report on 181 patientsD M McDonald-McGinn, D LaRossa, E Goldmuntz, et al.
Medrxiv : the Preprint Server for Health Sciences|February 7, 2023
Germline pathogenic variants in 786 neuroblastoma patientsJung Kim, Zalman Vaksman, Laura E Egolf, et al.
Journal of the National Cancer Institute|September 9, 2023
Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survivalJung Kim, Zalman Vaksman, Laura E Egolf, et al.
Pageof 22

Showing results (211-220 of 213) with videos related to

Sort By:
Pageof 22
You have reached the last page of results.This site can display upto 213 results.
Genetic Testing|January 1, 1997
The 22q11.2 deletion: screening, diagnostic workup, and outcome of results; report on 181 patientsD M McDonald-McGinn, D LaRossa, E Goldmuntz, et al.
Medrxiv : the Preprint Server for Health Sciences|February 7, 2023
Germline pathogenic variants in 786 neuroblastoma patientsJung Kim, Zalman Vaksman, Laura E Egolf, et al.
Journal of the National Cancer Institute|September 9, 2023
Germline pathogenic variants in neuroblastoma patients are enriched in BARD1 and predict worse survivalJung Kim, Zalman Vaksman, Laura E Egolf, et al.
Pageof 22